Newswire (Published: Tuesday, April 11, 2017, Received: Thursday, April 6, 2017, 4:20:25 PM CDT)
Word Count: 596
Findings on Prostate Cancer Reported by Investigators at National Cancer Institute (Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low ...)
By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news originating from Bethesda, Maryland, by NewsRx correspondents, research stated, "Active surveillance is an established option for men with low risk prostate cancer. Multiparametric magnetic resonance imaging with magnetic resonance imaging-transrectal ultrasound fusion guided biopsy may better identify patients for active surveillance compared to systematic 12-core biopsy due to improved risk stratification."
Our news journalists obtained a quote from the research from National Cancer Institute, "To our knowledge the performance of multiparametric magnetic resonance imaging in following men on active surveillance with visible lesions is unknown. We evaluated multiparametric magnetic resonance imaging and magnetic resonance imaging-transrectal ultrasound fusion guided biopsy to monitor men on active surveillance. This retrospective review included men from 2007 to 2015 with prostate cancer on active surveillance in whom magnetic resonance imaging visible lesions were monitored by multiparametric magnetic resonance imaging and fusion guided biopsy. Progression was defined by ISUP ( International Society of Urological Pathology) grade group 1 to 2 and ISUP grade group 2 to 3. Significance was considered at p<= 0.05. A total of 166 patients on active surveillance with 2 or more fusion guided biopsies were included in analysis. Mean followup was 25.5 months. Of the patients 29.5% had pathological progression. Targeted biopsy alone identified 44.9% of patients who progressed compared to 30.6% identified by systematic 12core biopsy alone ( p = 0.03). Fusion guided biopsy detected 26% more cases of pathological progression on surveillance biopsy compared to systematic 12-core biopsy. Progression on multiparametric magnetic resonance imaging was the sole predictor of pathological progression at surveillance biopsy ( p = 0.013). Multiparametric magnetic resonance imaging progression in the entire cohort had 81% negative predictive value, 35% positive predictive value, 77.6% sensitivity and 40.5% specificity in detecting pathological progression. Multiparametric magnetic resonance imaging progression predicts the risk of pathological progression. Patients with stable multiparametric magnetic resonance imaging findings have a low rate of progression."
According to the news editors, the research concluded: "Incorporating fusion guided biopsy in active surveillance nearly doubled our detection of pathological progression compared to systematic 12-core biopsy."
For more information on this research see: Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. Journal of Urology, 2017;197(3):640-646. Journal of Urology can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Journal of Urology - www.journals.elsevier.com/journal-of-urology/)
The news correspondents report that additional information may be obtained from P.A. Pinto, National Cancer Institute, Intervent Oncol, National Institutes of Health, Bethesda, MD 20892, United States. Additional authors for this research include A.K. George, A. Kilchevsky, M. Maruf, M.M. Siddiqui, M. Kongnyuy, A. Muthigi, H. Han, H.L. Parnes, M. Merino, P.L. Choyke, B. Turkbey, B. Wood and P.A. Pinto (see also Oncology - Prostate Cancer).
Keywords for this news article include: Bethesda, Maryland, United States, North and Central America, Cancer, Risk and Prevention, Epidemiology, Prostatic Neoplasms, Magnetic Resonance, Prostate Cancer, Oncology, National Cancer Institute.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
National Cancer Institute
National Institutes of Health
New York City
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices